Tag: CBT > DEA Scheduling: Page 7

Interviews & Opinion

Opinion: HHS Rescheduling Recommendation is 'About Damn Time'

The U.S. Department of Health and Human Services recognition that cannabis should no longer be classified in the same category as heroin is an event to be celebrated. But the trajectory of U.S. policy deserves to be mourned.

September 20, 2023

Cannabis Rescheduling

'Descheduling Would Not Be Utopia'

Shane Pennington of Porter Wright Morris & Arthur addresses some of the biggest questions and concerns surrounding cannabis rescheduling, including the role of the FDA and Big Pharma.

September 13, 2023

Cannabis Industry Research

The Impacts of Cannabis Rescheduling: Panelists Weigh In During International Cannabis Bar Association Webinar

Industry legal experts Khurshid Khoja, Amber Littlejohn and Shane Pennington shared insight into what rescheduling could mean for taxes, research and federal enforcement.

September 12, 2023

Colorado

Colorado Governor to President Biden: ‘We Must Do Better’ on Federal Cannabis Reform

Gov. Jared Polis encouraged the president to move swiftly to reschedule cannabis and urged him to not let up on other incremental changes.

September 5, 2023

Cannabis Rescheduling

‘Rescheduling is Not Enough,’ And Other Reactions to HHS Recommendation on Cannabis

Cannabis industry responds with cautious optimism to the Department of Health and Human Services' call to reschedule the plant, noting the significance of the announcement but also the potential limitations of the move.

September 5, 2023

Cannabis Rescheduling

US Health and Human Services Department Recommends Cannabis Reclassified to Schedule III

The move from Schedule I to Schedule III would provide that cannabis has a federally accepted medical use, but the decision now goes to the DEA.

August 30, 2023

Interviews & Opinion

Opinion: Rescheduling Is Recriminalizing, Descheduling Is Decriminalizing

President of cannabis genetics company DNA Genetics, Rezwan Khan, weighs in on Biden's cannabis policy reform plan and how rescheduling or descheduling the plant would impact the industry.

August 29, 2023

Hemp Regulations in U.S.

DEA May Propose Regulations That Would Threaten the Hemp-Derived Cannabinoid Industry and Cast a Dark Cloud Over CBD Industry

The federal agency announced in early May that it plans to soon propose new rules that would classify synthetically derived cannabinoids as controlled substances and would decontrol CBD up to 0.1% THC on a weight-to-weight or weight-to-volume basis.

May 26, 2023

The Last Word

A Unified National Cannabis Policy

FDA’s new senior public health adviser Norman Birenbaum talks about the agency’s approach to hemp-derived products and cannabis regulation, and what may come next.

March 13, 2023

Hemp Research

Risky Research

January 5, 2023

2022 Election and Cannabis

Will Cannabis Policy Change?

Past reviews of cannabis’s Schedule I classification in the Controlled Substances Act—the most recent of which took five years and ended in 2016—have never moved the needle with the Drug Enforcement Agency. Many wonder if this time will be different with the directive coming from the president.

October 26, 2022

Legislation and Regulation

Biden's Order to Review Cannabis 'Truly Historic,' But What's at Stake?

Many industry experts agree removing cannabis from the list of Controlled Substances would be ideal. But a rescheduling could make things more complex—or even a 'disaster' for the state-legal industry.

October 26, 2022